Syndax Pharmaceuticals Inc’s filing revealed that its Chief Executive Officer Metzger Michael A unloaded Company’s shares for reported $2.58 million on Sep 08 ’25. In the deal valued at $16.41 per share,157,307 shares were sold. As a result of this transaction, Metzger Michael A now holds 298,661 shares worth roughly $5.1 million.
Then, MICHAEL METZGER bought 157,307 shares, generating $2,680,511 in total proceeds.
Before that, Podlesak Dennis sold 19,200 shares. Syndax Pharmaceuticals Inc shares valued at $304,170 were divested by the Director at a price of $15.84 per share. As a result of the transaction, Podlesak Dennis now holds 191,763 shares, worth roughly $3.28 million.
BTIG Research maintained its rating on August 05, 2025. It rated SNDX as “a Buy”.
Price Performance Review of SNDX
On Tuesday, Syndax Pharmaceuticals Inc [NASDAQ:SNDX] saw its stock fall -0.52% to $17.09. Over the last five days, the stock has lost -3.61%. Syndax Pharmaceuticals Inc shares have risen nearly 1.79% since the year began. Nevertheless, the stocks have risen 29.27% over the past one year. While a 52-week high of $18.00 was reached on 11/13/25, a 52-week low of $8.58 was recorded on 05/15/25.
Levels Of Support And Resistance For SNDX Stock
The 24-hour chart illustrates a support level at 16.85, which if violated will result in even more drops to 16.60. On the upside, there is a resistance level at 17.39. A further resistance level may holdings at 17.68.
How much short interest is there in Syndax Pharmaceuticals Inc?
A steep rise in short interest was recorded in Syndax Pharmaceuticals Inc stocks on 2025-10-31, growing by 2.54 million shares to a total of 25.34 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 22.81 million shares. There was a rise of 10.01%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 10, 2025 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $18 price target.
